← Leaderboards
Dmitry Shayakhmetov
University Of Washington
$15,184,716
Attributed
$18,424,743
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,424,743 · 8
By mechanism
R01$16,909,366 · 4
R21$1,515,377 · 4
Top collaborators
- Phoebe L Stewart10 shared
Most similar at University Of Washington
Same institution · by research overlap
- Andre Michael Lieber$20,253,196
- Barbara Ensoli$1,708,483
- Marjorie Robert-Guroff$2,142,617
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMolecularIn VivoVectorVirusImmune ResponseAdenovirus VectorClinical TrialsAdenovirusesGene TransferMediatingIntravenousBaseCell TypeInflammatoryMalignant NeoplasmsViralInfectionInflammatory ResponseLeadResponseBloodCytokineDose
Grant awards (41)
Mechanistic factors limiting utility of adenovirus vectors for treatment of neopla$617,795
R01 · FY2025 · CA · contact PI
Mechanisms of adenovirus neutralization$687,160
R01 · FY2024 · AI · contact PI
Mechanistic factors limiting utility of adenovirus vectors for treatment of neopla$590,956
R01 · FY2024 · CA · contact PI
Mechanisms of adenovirus neutralization$691,611
R01 · FY2023 · AI · contact PI
Mechanistic factors limiting utility of adenovirus vectors for treatment of neopla$613,600
R01 · FY2023 · CA · contact PI
Mechanisms of adenovirus neutralization$695,929
R01 · FY2022 · AI · contact PI
Mechanistic factors limiting utility of adenovirus vectors for treatment of neopla$632,232
R01 · FY2022 · CA · contact PI
Mechanisms of adenovirus neutralization$700,122
R01 · FY2021 · AI · contact PI
Mechanisms of adenovirus neutralization$718,200
R01 · FY2020 · AI · contact PI
Innate immunity to adenovirus$390,000
R01 · FY2019 · AI · contact PI
Adenovirus hexon and its role in virus interaction with the host$582,164
R01 · FY2018 · AI · contact PI
Innate immunity to adenovirus$390,000
R01 · FY2018 · AI · contact PI
Adenovirus hexon and its role in virus interaction with the host$605,092
R01 · FY2017 · AI · contact PI
Innate immunity to adenovirus$390,000
R01 · FY2017 · AI · contact PI
Biogenesis of IL-1a in inflammatory process$234,000
R21 · FY2017 · AI · contact PI
Adenovirus hexon and its role in virus interaction with the host$619,306
R01 · FY2016 · AI · contact PI
Innate immunity to adenovirus$592,500
R01 · FY2016 · AI · contact PI
Biogenesis of IL-1a in inflammatory process$195,000
R21 · FY2016 · AI · contact PI
Adenovirus hexon and its role in virus interaction with the host$587,464
R01 · FY2015 · AI · contact PI
Innate immunity to adenovirus$390,000
R01 · FY2015 · AI · contact PI
Adenovirus hexon and its role in virus interaction with the host$593,007
R01 · FY2014 · AI · contact PI
Innate immunity to adenovirus vectors$386,100
R01 · FY2014 · AI · contact PI
Adenovirus-host interactions and in vivo virus targeting$373,905
R01 · FY2013 · CA · contact PI
Innate immunity to adenovirus vectors$362,934
R01 · FY2013 · AI · contact PI
Adenovirus-host interactions and in vivo virus targeting$412,933
R01 · FY2012 · CA · contact PI
Innate immunity to adenovirus vectors$386,100
R01 · FY2012 · AI · contact PI
Adenovirus-host interactions and in vivo virus targeting$494,102
R01 · FY2011 · CA · contact PI
Innate immunity to adenovirus vectors$386,100
R01 · FY2011 · AI · contact PI
Adenovirus-host interactions and in vivo virus targeting$545,162
R01 · FY2010 · CA · contact PI
Innate immunity to adenovirus vectors$521,241
R01 · FY2010 · AI · contact PI
Adenovirus-host interactions and in vivo virus targeting$548,316
R01 · FY2009 · CA · contact PI
Innate immunity to adenovirus vectors$282,026
R01 · FY2009 · AI · contact PI
Innate immunity to adenovirus vectors$282,026
R01 · FY2008 · AI · contact PI
Innate immunity to adenovirus vectors$287,488
R01 · FY2007 · AI · contact PI
Hexon-modified adenovirus vectors$227,154
R21 · FY2007 · AI · contact PI
Innate immunity to adenovirus vectors$296,075
R01 · FY2006 · AI · contact PI
Hexon-modified adenovirus vectors$194,375
R21 · FY2006 · AI · contact PI
Targeted adenovirus vectors for systemic application$185,048
R21 · FY2006 · AI · contact PI
Innate immunity to adenovirus vectors$257,720
R01 · FY2005 · AI
Targeted adenovirus vectors for systemic application$214,500
R21 · FY2005 · AI
Molecular Mechanisms of Systemic Adenovirus Toxicity$265,300
R21 · FY2004 · AI